Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 300

The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.

The Prostate Health Index Selectively Identifies Clinically Significant Prostate Cancer

Open access
Loeb, Stacy, Sanda, Martin G., Broyles, Dennis L., Shin, Sanghyuk S., Bangma, Chris H., Wei, John T., Partin, Alan W., Klee, George G., Slawin, Kevin M., Marks, Leonard S., van Schaik, Ron H.N., Chan, Daniel W., Sokoll, Lori J., Cruz, Amabelle B., Mizrahi, Isaac A., Catalona, William J.·2015·Journal of Urology

Abstract

PURPOSE: The Prostate Health Index (phi) is a new test combining total, free and [-2]proPSA into a single score. It was recently approved by the FDA and is now commercially available in the U.S., Europe and Australia. We investigate whether phi improves specificity for detecting clinically significant prostate cancer and can help reduce prostate cancer over diagnosis. MATERIALS AND METHODS: From a multicenter prospective trial we identified 658 men age 50 years or older with prostate specific antigen 4 to 10 ng/ml and normal digital rectal examination who underwent prostate biopsy. In this population we compared the performance of prostate specific antigen, % free prostate specific antigen, [-2]proPSA and phi to predict biopsy results and, specifically, the presence of clinically significant prostate cancer using multiple criteria. RESULTS: The Prostate Health Index was significantly higher in men with Gleason 7 or greater and "Epstein significant" cancer. On receiver operating characteristic analysis phi had the highest AUC for overall prostate cancer (AUCs phi 0.708, percent free prostate specific antigen 0.648, [-2]proPSA 0.550 and prostate specific antigen 0.516), Gleason 7 or greater (AUCs phi 0.707, percent free prostate specific antigen 0.661, [-2]proPSA 0.558, prostate specific antigen 0.551) and significant prostate cancer (AUCs phi 0.698, percent free prostate specific antigen 0.654, [-2]proPSA 0.550, prostate specific antigen 0.549). At the 90% sensitivity cut point for phi (a score less than 28.6) 30.1% of patients could have been spared an unnecessary biopsy for benign disease or insignificant prostate cancer compared to 21.7% using percent free prostate specific antigen. CONCLUSIONS: The new phi test outperforms its individual components of total, free and [-2]proPSA for the identification of clinically significant prostate cancer. Phi may be useful as part of a multivariable approach to reduce prostate biopsies and over diagnosis.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.juro.2014.10.121

Cites

17 of 17 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 17 references

Cited by

See all 300

Metadata

Authors
Loeb, S., Sanda, M. G., Broyles, D. L., Shin, S. S., Bangma, C. H., Wei, J. T., Partin, A. W., Klee, G. G., Slawin, K. M., Marks, L. S., van Schaik, R. H. N., Chan, D. W., Sokoll, L. J., Cruz, A. B., Mizrahi, I. A., & Catalona, W. J.
Venue
Journal of Urology
Published
2015-04
Volume
193
Issue
4
Pages
1163-1169
ISSN
  • 0022-5347 (ISSN-L)
  • 1527-3792
OpenAlex
W1970876554
Cited by
300
References
17
FWCI
19.14
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The Prostate Health Index Selectively Identifies Clinically Significant Prostate Cancer. https://app.cochat.ai/papers/10.1016/j.juro.2014.10.121
The paper
Loeb, S., Sanda, M. G., Broyles, D. L., Shin, S. S., Bangma, C. H., Wei, J. T., Partin, A. W., Klee, G. G., Slawin, K. M., Marks, L. S., van Schaik, R. H. N., Chan, D. W., Sokoll, L. J., Cruz, A. B., Mizrahi, I. A., & Catalona, W. J. (2015). The Prostate Health Index Selectively Identifies Clinically Significant Prostate Cancer. Journal of Urology. https://doi.org/10.1016/j.juro.2014.10.121

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.